PhaseBio
is a biopharmaceutical firm that researches and develops novel therapeutics for the treatment of orphan diseases... Read morePhaseBio
is a biopharmaceutical firm that researches and develops novel therapeutics for the treatment of orphan diseases... Read more
News
Mar 11, 2024
Orrick
PhaseBio: Orrick Advises SFJ Pharmaceuticals on Acquisition of Bentracimab Assets from PhaseBio
Feb 06, 2023
ChinaBio Today
PhaseBio: Ji Xing Buys Global Rights for Hypertension Candidate from PhaseBio
Feb 01, 2023
Global Legal Chronicle
PhaseBio: SFJ Pharmaceuticals' Acquisition of Bentracimab Assets
Jan 18, 2023
Endpoints News
PhaseBio: Bankrupt PhaseBio settles with investor-partner, handing off late-stage drug
Jan 05, 2023
The Business Journals
PhaseBio: Bankruptcy court approves PhaseBio's $32.9M asset transfer deal
Dec 21, 2022
Wkrn
PhaseBio: Delisting of Securities of PhaseBio Pharmaceuticals, Inc.; Zovio Inc.; Fast Radius, Inc.; and Kismet Acquisition Three Corp. from The Nasdaq Stock Market
Nov 23, 2022
Marketscreener
PhaseBio: PhaseBio Pharmaceuticals, Inc. Announces Resignation of John P. Sharp as Chief Financial Officer, Effective November 30, 2022
Oct 24, 2022
The Business Journals
PhaseBio: PhaseBio files for bankruptcy, has a potential deal to sell its assets for up to $60M
Oct 19, 2022
The Business Journals
PhaseBio: Cash-strapped PhaseBio sued by drug development partner in dispute over experimental therapy
Sep 29, 2022
BioSpace
PhaseBio: SFJ Says PhaseBio Must Return Rights to Lead Program
